Translational Hematology

Our research is focused on the discovery of novel treatment strategies in difficult-to-treat hematologic malignancies such as Acute Leukemias and Aggressive Lymphomas.

The main field of interest is the study of chemoresistant lymphoma and leukemia specific vulnerabilities for the implementation of novel therapies based on synthetic lethalities.

We are especially interested in targeting synthetic lethalities in MYC-driven aggressive lymphomas and TP53 mutant leukemias, focusing on MYC, BCL-2, MCL-1, DNA repair and telomere dysfunction. On the other hand, we are implementing novel strategies to enhance the efficacy of current immunotherapies including chimeric antigen receptor (CAR) T and NK-cell therapy.

For these aims we employ preclinical leukemia and lymphoma models, large scale multi-omics profiling and we interrogate publicly available annotated clinical datasets.

The main goal of our lab is the rapid transition of preclinical findings in precision-therapy clinical trials. Another goal of our research is the identification of biomarkers allowing response prediction, which could useful for better selection of patients for precision-therapy approaches.